226. 間質性膀胱炎（ハンナ型） Disease details / Clinical trials / Drug dev / DR info

2% sodium chondroitin sulfate
   Watson Pharmaceuticals
      2009   Phase 2   NCT00919113   United States
40MG triamcinolone injections IN THE bladder
   The University of Texas Medical Branch, Galveston
      2022   -   NCT05226832   United States
5% lidocaine/5 MG/ML 0.02% estradiol compound cream
   Duke University
      2019   Phase 2   NCT03844412   United States
Adalimumab
   ICStudy, LLC
      2011   Phase 3   NCT01295814   United States
AGN 203818
   Allergan
      2006   Phase 2   NCT00380783   United States
Alkalinized lidocaine-heparin
   Urigen
      2006   Phase 2   NCT00256542   United States
Allorx
   The Foundation for Orthopaedics and Regenerative Medicine
      2021   Phase 1   NCT05147779   Antigua and Barbuda
Amitriptyline
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   Phase 3   NCT00124306   Canada;United States
Amitriptyline/gabapentin
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
AQX-1125
   Aquinox Pharmaceuticals (Canada) Inc.
      2017   Phase 3   EUCTR2016-000906-12-NL   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000906-12-ES   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000906-12-BE   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000906-12-LV   Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000906-12-HU   Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000906-12-GB   Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000906-12-DK   Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000906-12-CZ   Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
      2013   Phase 2   NCT01882543   Canada;United States
AQX-1125 100 MG
   Aquinox Pharmaceuticals (Canada) Inc.
      2016   Phase 3   NCT02858453   Belgium;Canada;Czech Republic;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
AQX-1125 200 MG
   Aquinox Pharmaceuticals (Canada) Inc.
      2016   Phase 3   NCT02858453   Belgium;Canada;Czech Republic;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States
ASP3652
   Astellas Pharma Europe B.V.
      2013   -   EUCTR2011-004555-39-LT   Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   Phase 2   NCT01613586   Belgium;Czech Republic;Czechia;Denmark;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-PT   Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-PL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-NL   Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-LV   Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-ES   Belgium;Czech Republic;Denmark;France;Germany;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-DK   Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-DE   Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   -   EUCTR2011-004555-39-CZ   Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
      2012   Phase 2   EUCTR2011-004555-39-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain
ASP6294
   Astellas Pharma Europe B.V.
      2017   Phase 2   NCT03282318   Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-PL   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-NL   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-LV   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-HU   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-GB   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-ES   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-DE   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-CZ   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
      2017   Phase 2   EUCTR2016-004138-12-BE   Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
Atogepant
   The Cleveland Clinic
      2024   -   NCT06212661   United States
Behavioral health consultation/therapy
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
Bladder instillation
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
Bladder instillation with heparin/ lidocaine
   Scripps Health
      2012   Phase 2   NCT01048177   United States
Bladder instillation with triamcinolone acetonide
   Olivia Cardenas-Trowers, M.D.
      2019   Phase 3   NCT03463915   United States
Bladder instillation without triamcinolone acetonide
   Olivia Cardenas-Trowers, M.D.
      2019   Phase 3   NCT03463915   United States
Bladder instillations
   William Beaumont Hospitals
      2017   Phase 2   NCT02870738   United States
Bladder tissue OF interstitial cystitis and normal bladder tissue
   Samsung Medical Center
      2018   -   NCT03523559   Korea, Republic of
Botox
   AbbVie
      2022   Phase 2   NCT05141006   Canada;United States
   University of Washington
      2004   Phase 4   NCT00194610   United States
   research office urology VUmc
      2008   -   EUCTR2007-005164-27-NL   Netherlands
Botox 100U IN normal saline
   Buddhist Tzu Chi General Hospital
      2021   Phase 2   NCT05275647   Taiwan
Botox 200U IN normal saline
   Buddhist Tzu Chi General Hospital
      2014   Phase 2   NCT02247557   Taiwan
Botulinum toxin A
   Buddhist Tzu Chi General Hospital
      2012   Phase 2   NCT01969773   Taiwan
   The Cleveland Clinic
      2024   -   NCT06212661   United States
Buckwheat
   Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka
      2017   -   JPRN-UMIN000029113   Japan
Bupivacaine
   Case Western Reserve University
      2009   -   NCT01616992   United States
   NorthShore University HealthSystem
      2011   Phase 4   NCT05223244   -
Cannabidiol vaginal suppository
   University of New Mexico
      2021   Phase 1   NCT04349930   United States
Capsaicin
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1995   Phase 1/Phase 2   NCT00004316   United States
Cascade
   The First Hospital of China Medical University
      2024   -   ChiCTR2400080469   China
Certolizumab pegol
   ICStudy, LLC
      2015   Phase 3   NCT02497976   United States
Ciclosporin
   Oulu University Hospital
      2015   Phase 2   EUCTR2015-004495-30-FI   Finland
Ciklosporin
   Ingrid Ehrén
      2005   -   EUCTR2005-000890-23-SE   Sweden
Clarix FLO
   Case Western Reserve University
      2024   Phase 3   NCT06104787   -
   David Sheyn
      2024   Phase 2/Phase 3   NCT06096597   United States
Cyclosporine
   The Cleveland Clinic
      2013   Phase 2   NCT01990898   United States
Desert harvest aloe vera capsules
   Wake Forest University Health Sciences
      2025   Early Phase 1   NCT04734106   United States
Dexmedetomidine
   University of Rochester
      2010   Phase 4   NCT01195116   United States
Dextrose
   National Defense Medical Center, Taiwan
      2019   -   NCT04821882   Taiwan
Dimethyl sulfoxide
   Capital District Health Authority, Canada
      2006   Phase 2   NCT00317070   Canada
   IBSA
      2011   -   EUCTR2010-021556-25-IT   Italy
   Kyorin Pharmaceutical Co.,LTD
      2017   Phase 3   JPRN-jRCT2080223511   Japan
   NorthShore University HealthSystem
      2011   Phase 4   NCT05223244   -
   West China Hospital, Sichuan University
      2023   -   ChiCTR2300070519   China
Dmso
   Assaf-Harofeh Medical Center
      2010   -   NCT01069263   Israel
   Deparment of Urology, Medical Science, University of Fukui
      2005   -   JPRN-UMIN000003172   Japan
   Department of Urology, Hamamatsu University School of Medicine
      2004   -   JPRN-UMIN000027494   Japan
   NorthShore University HealthSystem
      2011   Phase 4   NCT05223244   -
   Urology, Hokkaido University Graduate School of Medicine
      2014   -   JPRN-UMIN000014860   Japan
Dmso cocktail
   Assaf-Harofeh Medical Center
      2009   -   NCT01074567   Israel
Eptinezumab
   The Cleveland Clinic
      2024   -   NCT06212661   United States
ERB-041
   Wyeth is now a wholly owned subsidiary of Pfizer
      2006   -   NCT00275379   Austria;Germany;United States
Erenumab
   The Cleveland Clinic
      2024   -   NCT06212661   United States
Ferumoxytol
   Christopher J Chermansky, MD
      2023   Early Phase 1   NCT05811377   United States
Flavoxate
   Torimoto Kazumasa
      2021   Phase 2   JPRN-jRCTs051210106   -
Fospropofol (lusedra®) 10
   Grace Shih, MD
      2011   -   NCT01378754   United States
Fospropofol (lusedra®) 6.5
   Grace Shih, MD
      2011   -   NCT01378754   United States
Fremanezumab
   Teva Branded Pharmaceutical Products R&D, Inc.
      2020   Phase 2   NCT04447729   -
   The Cleveland Clinic
      2024   -   NCT06212661   United States
Gadobutrol
   Christopher J Chermansky, MD
      2023   Early Phase 1   NCT05811377   United States
Galcanezumab
   The Cleveland Clinic
      2024   -   NCT06212661   United States
Gefapixant
   Afferent Pharmaceuticals, Inc.
      2012   Phase 2   NCT01569438   United States
Glucose
   Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP)
      2013   -   JPRN-jRCT1091220113   Japan
Glycine
   Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP)
      2013   -   JPRN-jRCT1091220113   Japan
Gralise
   Shirley Ryan AbilityLab
      2012   Phase 4   NCT01678911   United States
Heparin
   Department of Urology and Renal transplantation, Nagasaki University Hospital
      2016   -   JPRN-UMIN000027918   Japan
   Department of Urology, Mitsui Memorial Hospital
      2016   Phase 2,3   JPRN-UMIN000026714   Japan
   NorthShore University HealthSystem
      2011   Phase 4   NCT05223244   -
   The First Hospital of China Medical University
      2024   -   ChiCTR2400080469   China
   University of Tokushima
      2011   Phase 2   JPRN-UMIN000006387   Japan
   Urigen
      2015   Phase 2   NCT02591199   United States
   Vaneltix Pharma, Inc.
      2023   Phase 2   NCT05737121   United States
Heparin & alkalinized lidocaine bladder instillation
   Walter Reed National Military Medical Center
      2020   Phase 2   NCT05414305   United States
      2020   Phase 2   NCT04401176   United States
High density surface electromyographic, precision botulinum neurotoxin injection guidance medical device
   HillMed Inc.
      2024   Early Phase 1   NCT05062902   United States
Hyaluronic acid and chondroitin sulfate
   Samsung Medical Center
      2017   -   NCT03463499   Korea, Republic of
Hyaluronic acid/chondroitin sulfate
   Asan Medical Center
      2013   -   NCT01813565   Korea, Republic of
Hydrogen
   Koushinkai Hospital
      2008   Phase 2,3   JPRN-UMIN000001253   Japan
Hyperbaric oxygen therapy
   Assaf-Harofeh Medical Center
      2010   -   NCT01069263   Israel
IC cocktail
   Capital District Health Authority, Canada
      2006   Phase 2   NCT00317070   Canada
Immunonutrition
   Centre Hospitalier Universitaire Vaudois
      2023   Phase 3   NCT05726786   Switzerland
Inactive drug
   ICStudy, LLC
      2011   Phase 3   NCT01295814   United States
Injections ON posterior bladder wall excluding THE trigone
   Wake Forest University Health Sciences
      2014   Phase 4   NCT02297100   United States
Injections upper aspect OF trigone OF urinary bladder
   Wake Forest University Health Sciences
      2014   Phase 4   NCT02297100   United States
Interferential current
   Cairo University
      2019   -   NCT03844581   Egypt
Interferon
   West China Hospital
      2023   Phase 2/Phase 3   NCT05912946   -
Intermittent exposure TO oxygen VIA ORO-nasal mask
   University of South Florida
      2016   -   NCT03693001   -
Intravesical onabotulinumtoxina injection
   Buddhist Tzu Chi General Hospital
      2015   Phase 2   NCT03076762   Taiwan
Intravesical ozone therapy
   Medipol University
      2025   -   NCT06863220   Turkey
IW-3300 rectal foam
   Ironwood Pharmaceuticals, Inc.
      2023   Phase 2   NCT05740007   United States
JNJ-42160443
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2010   Phase 2   NCT01060254   Canada;United States
Ketorolac tromethamine
   Citrus Valley Medical Research, Inc.
      2012   Phase 4   NCT02000401   United States
Lidocaine
   Allergan
      2011   Phase 2   NCT01475253   Canada;United States
   Department of Urology and Renal transplantation, Nagasaki University Hospital
      2016   -   JPRN-UMIN000027918   Japan
   Department of Urology, Mitsui Memorial Hospital
      2016   Phase 2,3   JPRN-UMIN000026714   Japan
   Johns Hopkins University
      2015   -   NCT02517996   United States
   North Shore Long Island Jewish Health System
      2009   -   NCT00823030   United States
   The First Hospital of China Medical University
      2024   -   ChiCTR2400080469   China
   Urigen
      2015   Phase 2   NCT02591199   United States
   Vaneltix Pharma, Inc.
      2023   Phase 2   NCT05737121   United States
Liposome encapsulated BONT-A
   Buddhist Tzu Chi General Hospital
      2014   Phase 2   NCT02247557   Taiwan
Liposomes
   Kenneth Peters, MD
      2012   -   NCT01731470   United States
      2010   -   NCT01083979   United States
Liris 400 MG
   Allergan
      2013   Phase 2   NCT01824303   Canada;United States
Liris LOW dose and liris high dose
   Allergan
      2010   Phase 1   NCT01150565   Canada
Liris® 400 MG
   Allergan
      2013   Phase 1   NCT01879683   United States
LOW-dose naltrexone
   NorthShore University HealthSystem
      2021   Phase 4   NCT04313972   United States
LP-08 20MG
   Lipella Pharmaceuticals, Inc.
      2015   Phase 2   NCT01393223   United States
LP-08 80MG
   Lipella Pharmaceuticals, Inc.
      2015   Phase 2   NCT01393223   United States
Methenamine
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
Metoprolol tartrate oral tablet
   Virginia Commonwealth University
      2017   Phase 4   NCT03008382   United States
Mirabegron
   Department of Urology, Graduate school of medicine, University of Tokyo
      2012   -   JPRN-UMIN000008484   Japan
   Philadelphia Urosurgical Associates
      2016   Phase 3   NCT02787083   United States
MMF
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2007   Phase 3   NCT00451867   Canada;United States
MN-001 BID
   MediciNova
      2005   Phase 2   NCT00295854   United States
MR-MC-01
   Asan Medical Center
      2020   Phase 1   NCT04610359   Korea, Republic of
Multimodal bundle drugs
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
Mycophenolate mofetil
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2007   Phase 3   NCT00451867   Canada;United States
Naloxone hydrochloride
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Naltrexone
   Stanford University
      2020   Phase 2   NCT04450316   United States
NO intervention- observational SUB-study
   Virginia Commonwealth University
      2017   Phase 4   NCT03008382   United States
Normal saline
   Lipella Pharmaceuticals, Inc.
      2015   Phase 2   NCT01393223   United States
   Medipol University
      2025   -   NCT06863220   Turkey
   North Shore Long Island Jewish Health System
      2009   -   NCT00823030   United States
   University of Rochester
      2010   Phase 4   NCT01195116   United States
   University of Washington
      2004   Phase 4   NCT00194610   United States
Normal saline instillation
   Buddhist Tzu Chi General Hospital
      2012   Phase 2   NCT01969773   Taiwan
Nortriptyline
   Duke University
      2019   Phase 2   NCT03844412   United States
Omalizumab
   IRCCS Policlinico S. Matteo
      2009   Phase 3   NCT01294878   Italy
Onabotulinum toxin A
   Walter Reed National Military Medical Center
      2020   Phase 2   NCT04401176   United States
Onabotulinumtoxin A
   Wake Forest University Health Sciences
      2014   Phase 4   NCT02297100   United States
ONO-1110
   Ono Pharmaceutical Co. Ltd
      2025   Phase 2   NCT06752603   Japan
Operative cystoscopy
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
OXN 10/5 MG PR
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
OXN 20/10 MG PR
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
OXN 5/2.5 MG PR
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Oxycodone hydrochloride
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Oxycodone naloxone prolonged release tablets
   Mundipharma Research GmbH & Co KG
      2010   Phase 2   NCT01197261   Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom
Oxycodone/naloxone prolonged release T
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Oxycodone/naloxone prolonged release tablets 10/5 MG
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Oxycodone/naloxone prolonged release tablets 20/10 MG
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Oxycodone/naloxone prolonged release tablets 5/2.5 MG
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Oxytocin
   University of Alabama at Birmingham
      2010   Phase 4   NCT00919802   United States
Ozone
   Anhembi Morumbi University
      2020   Phase 2   NCT04789135   Brazil
   Second Hospital of Tianjin Medical University
      2024   -   ChiCTR2400083297   China
PD 0299685
   Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
      2008   -   EUCTR2008-002421-37-FI   Denmark;Finland;France;Germany
      2008   -   EUCTR2008-002421-37-DK   Denmark;Finland;France;Germany
      -   -   EUCTR2008-002421-37-DE   Denmark;Finland;France;Germany
PD 0299685 AT 15MG BID
   Pfizer
      2008   Phase 2   NCT00739739   Canada;Denmark;Finland;France;Germany;United States
PD 0299685 AT 30MG BID
   Pfizer
      2008   Phase 2   NCT00739739   Canada;Denmark;Finland;France;Germany;United States
PD-0299685
   Pfizer Ltd;Ramsgate Road,Sandwich,Kent CT13 9NJ
      2008   Phase 2   EUCTR2008-002421-37-FR   Denmark;Finland;France;Germany
Pelvic floor physical therapy
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
   William Beaumont Hospitals
      2017   Phase 2   NCT02870738   United States
Pentosan polysulfate sodium 100 MG
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2003   Phase 4   NCT00086684   Canada;United States
PF-04383119
   Pfizer
      2008   Phase 2   NCT00601484   United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2010   Phase 2   EUCTR2009-014597-17-SK   Belgium;Finland;Germany;Slovakia;Spain;Sweden
      2010   -   EUCTR2009-014597-17-SE   Belgium;Finland;Germany;Spain;Sweden
      2010   Phase 2   EUCTR2009-014597-17-FI   Belgium;Finland;Germany;Slovakia;Spain;Sweden
      2010   -   EUCTR2009-014597-17-DE   Belgium;Finland;Germany;Spain;Sweden
      2009   Phase 2   EUCTR2009-014597-17-BE   Belgium;Finland;Germany;Slovakia;Spain;Sweden
   Pfizer, S.A.
      2010   -   EUCTR2009-014597-17-ES   Belgium;Finland;Germany;Spain;Sweden
Platelet enriched plasma
   Mansoura University
      2019   Phase 1/Phase 2   NCT04118946   Egypt
Platelet-rich plasma
   Buddhist Tzu Chi General Hospital
      2017   Phase 1   NCT03104361   Taiwan
Prograf
   Jukka Sairanen
      2008   -   EUCTR2008-001501-42-FI   Finland
Propiverine hydrochloride
   Cairo University
      2019   -   NCT03844581   Egypt
PRP
   Ain Shams University
      2021   Phase 3   NCT06209008   Egypt
Rimegepant
   The Cleveland Clinic
      2024   -   NCT06212661   United States
Rimso 50
   IBSA
      2011   -   EUCTR2010-021556-25-IT   Italy
RN624, RI624
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2010   Phase 2   EUCTR2009-014597-17-SK   Belgium;Finland;Germany;Slovakia;Spain;Sweden
      2010   -   EUCTR2009-014597-17-SE   Belgium;Finland;Germany;Spain;Sweden
      2010   Phase 2   EUCTR2009-014597-17-FI   Belgium;Finland;Germany;Slovakia;Spain;Sweden
      2010   -   EUCTR2009-014597-17-DE   Belgium;Finland;Germany;Spain;Sweden
      2009   Phase 2   EUCTR2009-014597-17-BE   Belgium;Finland;Germany;Slovakia;Spain;Sweden
   Pfizer, S.A.
      2010   -   EUCTR2009-014597-17-ES   Belgium;Finland;Germany;Spain;Sweden
Saline AS A nasal spray
   University of Alabama at Birmingham
      2010   Phase 4   NCT00919802   United States
Sandimmun
   Oulu University Hospital
      2015   Phase 2   EUCTR2015-004495-30-FI   Finland
Sandimmun neoral
   Ingrid Ehrén
      2005   -   EUCTR2005-000890-23-SE   Sweden
Sham cystoscopy procedure
   Allergan
      2011   Phase 2   NCT01475253   Canada;United States
SI-722
   Seikagaku Corporation
      2020   Phase 1/Phase 2   NCT04208087   United States
Sildenafil
   The First Af?liated Hospital of Wenzhou Medical College
      2009   -   ChiCTR-TRC-13003938   China
Sodium bicarbonate
   The First Hospital of China Medical University
      2024   -   ChiCTR2400080469   China
Sodium chloride injection
   West China Hospital
      2023   Phase 2/Phase 3   NCT05912946   -
Sodium hyaluronate
   MEDA Pharma GmbH & Co. KG
      2022   -   NCT05544695   Austria
   West China Hospital
      2023   Phase 2/Phase 3   NCT05912946   -
Suplatast tosilate
   Astellas Pharma Europe B.V.
      2006   -   EUCTR2005-003367-23-SE   Germany;Sweden
      2006   Phase 2   EUCTR2005-003367-23-DK   Denmark;Germany;Sweden
      2006   -   EUCTR2005-003367-23-DE   Germany;Sweden
   Taiho Pharmaceutical Co., Ltd.
      2006   Phase 3   JPRN-jRCT2080220253   -
Tacrolimus
   Jukka Sairanen
      2008   -   EUCTR2008-001501-42-FI   Finland
Tanezumab
   Pfizer
      2010   Phase 2   NCT00999518   Belgium;Canada;Finland;Germany;Hong Kong;India;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;United States
      2009   Phase 1   NCT01030640   United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2010   Phase 2   EUCTR2009-014597-17-SK   Belgium;Finland;Germany;Slovakia;Spain;Sweden
      2010   -   EUCTR2009-014597-17-SE   Belgium;Finland;Germany;Spain;Sweden
      2010   Phase 2   EUCTR2009-014597-17-FI   Belgium;Finland;Germany;Slovakia;Spain;Sweden
      2010   -   EUCTR2009-014597-17-DE   Belgium;Finland;Germany;Spain;Sweden
      2009   Phase 2   EUCTR2009-014597-17-BE   Belgium;Finland;Germany;Slovakia;Spain;Sweden
   Pfizer, S.A.
      2010   -   EUCTR2009-014597-17-ES   Belgium;Finland;Germany;Spain;Sweden
Targinact 10 MG/5 MG prolonged-release tablets
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Targinact 20MG/10 MG prolonged-release tablets
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Targinact 5MG/2.5 MG prolonged-release tablets
   Mundipharma Research GmbH & Co. KG
      2010   -   EUCTR2009-018118-21-HU   Czech Republic;Germany;Hungary;United Kingdom
      2010   Phase 2   EUCTR2009-018118-21-GB   Czech Republic;Germany;Hungary;United Kingdom
      2010   -   EUCTR2009-018118-21-CZ   Czech Republic;Germany;Hungary;United Kingdom
      -   -   EUCTR2009-018118-21-DE   Czech Republic;Germany;Hungary;United Kingdom
Tramadol
   Departmen of Urology, The University of Tokyo Hospital
      2014   -   JPRN-UMIN000009197   Japan
Transvaginal botulinum toxin A (BTA) injection
   Stanford University
      2022   Early Phase 1   NCT05485207   United States
Triamcinolone
   NorthShore University HealthSystem
      2011   Phase 4   NCT05223244   -
TTI-1612
   Trillium Therapeutics Inc.
      2012   Phase 1   NCT01559961   Canada
Ubrogepant
   The Cleveland Clinic
      2024   -   NCT06212661   United States
URG101
   Urigen
      2015   Phase 2   NCT02591199   United States
      2007   Phase 2   NCT00517868   United States
Urodynamic study
   North Shore Long Island Jewish Health System
      2009   -   NCT00823030   United States
Usual urogynecologic care
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
V117957
   Imbrium Therapeutics
      2022   Phase 1   NCT06285214   United States
Vaginal estrogen
   Jocelyn Fitzgerald
      2022   Phase 3   NCT05658874   United States
VNX001
   Vaneltix Pharma, Inc.
      2024   Phase 2   NCT06394830   United States
      2023   Phase 2   NCT05737121   United States
Water
   Koushinkai Hospital
      2008   Phase 2,3   JPRN-UMIN000001253   Japan
   Second Hospital of Tianjin Medical University
      2024   -   ChiCTR2400083297   China
   The First Hospital of China Medical University
      2024   -   ChiCTR2400080469   China
YM672
   Astellas Pharma Europe B.V.
      2006   -   EUCTR2005-003367-23-SE   Germany;Sweden
      2006   Phase 2   EUCTR2005-003367-23-DK   Denmark;Germany;Sweden
      2006   -   EUCTR2005-003367-23-DE   Germany;Sweden